8.18
-0.17(-2.04%)
Currency In USD
| Previous Close | 8.35 |
| Open | 8.66 |
| Day High | 8.74 |
| Day Low | 8.02 |
| 52-Week High | 13.71 |
| 52-Week Low | 5.99 |
| Volume | 1.37M |
| Average Volume | 2.3M |
| Market Cap | 1.19B |
| PE | -2.33 |
| EPS | -3.51 |
| Moving Average 50 Days | 8.78 |
| Moving Average 200 Days | 8.43 |
| Change | -0.17 |
If you invested $1000 in 89bio, Inc. (ETNB) since IPO date, it would be worth $393.27 as of March 14, 2025 at a share price of $8.18. Whereas If you bought $1000 worth of 89bio, Inc. (ETNB) shares 5 years ago, it would be worth $498.78 as of March 14, 2025 at a share price of $8.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
89bio to Participate in the Leerink Partners Global Healthcare Conference
GlobeNewswire Inc.
Mar 03, 2025 9:05 PM GMT
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver
89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Feb 03, 2025 1:00 PM GMT
SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometaboli
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Jan 29, 2025 3:31 AM GMT
SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometaboli